NCT06747312View on ClinicalTrials.gov

Effect of Belimumab on Antibody Titers in Primary APS Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Antiphospholipid Syndrome (APS)
Interventions
DRUG

Belimumab+SOC

10mg/kg once a month for 18 months

DRUG

SOC

SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER